Resources
About Us
Home Report
Store
Viral Vaccines Market
Viral Vaccines Market Size, Share, Forecast, & Trends Analysis by Form (Liquid, Lyophilized) Type (Live Attenuated, mRNA, Inactivated), Route of Administration (Intramuscular, Subcutaneous, Oral), Approach, Indication, Packaging – Global Forecast to 2031
Report ID:MRHC - 1041237 Pages: 239 Nov-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe Viral Vaccines Market is expected to reach $64.18 billion by 2031, at a CAGR of 9.3% from 2024 to 2031.
Viral Vaccines Market Size & Forecast
The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.
Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market’s growth.
Viral Vaccines Market Growth Drivers
Technological Advancements in Vaccine Administration
Vaccine technology has evolved significantly during the last decade, profoundly changing the future of vaccine development. The introduction of genetic engineering has fuelled many advances in vaccine development programs, leading to new products. Various virus vaccines that use the attenuated form of the virus have been developed through these methods. Also, new technologies enable the faster detection of viruses and allow for concentration levels to be kept high enough to generate an immune response.
Recent vaccine technologies are largely driven by the need to accelerate response times against emerging threats and make vaccines available for quick deployment. The increasing need to develop vaccines against difficult targets and improve delivery systems for maximum potency is also the focus of innovation in the vaccine industry. The development of synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and nanoparticle delivery systems are a few of the technological advancements in vaccine delivery. Therefore, technological advancements are expected to drive the emergence of new and more effective vaccines for various new indications, fuelling the growth of the viral vaccines market.
Click here to: Get a Free Sample Copy of this report
Growing Focus on Therapeutic Vaccines
Historically, vaccines have been used primarily to prevent diseases, but a new category known as therapeutic vaccines has recently emerged. Therapeutic vaccines are designed to treat diseases by inducing or enhancing the body's immune response. Unlike preventive vaccines, which aim to prevent disease before it occurs, therapeutic vaccines target patients who are already affected by the disease, helping to treat or manage the condition. Since the success of the first therapeutic vaccine post-2010, key players in the vaccine industry have increasingly focused on developing therapeutic vaccines for various conditions, particularly cancers. For instance, as of May 2024, Pfizer Inc. (U.S.) has 17 vaccines in its pipeline, targeting diseases and infections such as influenza, hepatitis, Lyme disease, invasive group B streptococcus, and respiratory syncytial virus (RSV), among others.
Although therapeutic vaccines currently represent a small market—mainly limited to vaccines for skin, prostate, and bladder cancers, as well as a few for pollen allergies—this market is expected to expand significantly in the future. With growth projections outpacing those for preventive vaccines, therapeutic vaccines offer opportunities for manufacturers in the coming years.
Viral Vaccines Market Trends
Increasing Preference for Personalized Treatments
Personalized vaccines represent the latest advancement in immunization, designed to elicit immune responses against specific antigens and microorganisms tailored to an individual’s condition. These vaccines aim to establish long-lasting immunity while minimizing side effects. By customizing the vaccine to the patient's unique needs, personalized vaccines can improve safety profiles and reduce reactogenicity. Additionally, viral vectors used in these vaccines can be genetically modified to make them replication-deficient, further enhancing their safety.
Various personalized vaccines are being developed to target diseases, particularly different types of cancer. For instance, in April 2024, researchers from the American Association for Cancer Research (AACR) reported the development of a new therapeutic cancer vaccine, TG4050. This vaccine targets head and neck squamous cell carcinoma (HNSCC) and is based on an engineered form of the vaccinia virus. TG4050 delivers 30 personalized neoantigens that are unique to each patient's tumor, stimulating the activation of an antitumor immune response.
Media and Public Awareness Regarding Immunization
Public awareness plays a crucial role in sensitizing communities about the importance of vaccines and vaccination. Immunization is the process by which a person is protected from disease through vaccination. It is one of the most successful and cost-effective public health interventions, saving millions of lives each year. According to the World Health Organization (WHO), immunization prevents approximately 4-5 million deaths annually from infectious diseases such as hepatitis, tetanus, measles, and polio.
However, globally, around 1.15 million children in the Western Pacific Region miss out on essential vaccinations. In order to address this, governments and health organizations are organizing immunization programs to ensure that all individuals, including those in rural areas, receive vaccinations. For example, in December 2022, the National Technical Advisory Group on Immunization (NTAGI) in India recommended the introduction of the human papillomavirus (HPV) vaccine into the Universal Immunization Programme (UIP), with a one-time catch-up for girls aged 9-14, followed by routine vaccination for 9-year-olds.
Viral Vaccines Market Opportunity
Growing Focus on Therapeutic Vaccines
Therapeutic vaccines are generally administered after a disease or infection has affected the patient and they work by activating the immune system of a patient. Therapeutic vaccines are also being majorly used as a viable option for active immunotherapy of cancers. Unlike preventive vaccines, therapeutic vaccines can be customized to respond to specific mutations. These vaccines differ from traditional vaccines as they target the pathogens directly instead of producing antibodies and generating immune proteins. Apart from cancers, therapeutic vaccines can also be used to treat infections due to the human papillomavirus (HPV).
Recent times have witnessed remarkable developments and advancements in vaccine technologies to improve immunization in patients. Certain market players are also collaborating to develop new therapeutics for cancer treatment. For instance, in April 2024, CureVac SE (Germany) collaborated with the University of Texas MD Anderson Cancer Center (U.S.) to develop novel mRNA-based cancer vaccines.
Viral Vaccines Market Analysis: Key Findings
By Form: In 2024, the Liquid Vaccines Segment to Dominate the Viral Vaccines Market
Based on forms, the market is segmented into liquid vaccines and lyophilized vaccines. In 2024, the liquid vaccines segment is expected to account for the larger share of 78.9% of the viral vaccines market. Liquid viral vaccines are formulations containing live or weakened viruses, which serve as the primary component to induce an immune response in the body. These vaccines are typically administered via injection. The large share of this segment is attributed to factors such as ease of administration, reduced risk of errors, decreased wastage, improved patient experience, lower production costs, and enhanced stability. For instance, Bharat Biotech Ltd. (India), a manufacturer of vaccines and bio-therapeutics, offers a live attenuated rotavirus vaccine in its product portfolio. This liquid frozen vaccine contains the live rotavirus 116E strain and is used to prevent rotavirus gastroenteritis.
By Vaccine Type: In 2024, the mRNA Vaccines Segment to Dominate the Viral Vaccines Market
Based on vaccine types, the market is segmented into subunit & conjugate vaccines, live attenuated vaccines, inactivated vaccines, mRNA vaccines, viral vector vaccines, toxoid vaccines, and combination vaccines. In 2024, the mRNA vaccines segment is expected to account for the largest share of 63.1% of the viral vaccines market. mRNA vaccines are a type of genetic vaccine that uses messenger RNA (mRNA) to instruct cells to produce proteins that trigger an immune response against a specific virus. The large market share of this segment is attributed to several factors, including the superior stability of mRNA vaccines compared to other types, an effective delivery system, and the use of lipid nanoparticles, which help deliver the mRNA to cells by facilitating its attachment to the cell membrane.
By Approach: In 2024, the Preventive Vaccines Segment to Dominate the Viral Vaccines Market
Based on approaches, the market is segmented into preventive vaccines and therapeutic vaccines. In 2024, the preventive vaccines segment is expected to account for the larger share of the viral vaccines market. Preventive (or prophylactic) vaccines are designed to prevent diseases before exposure to pathogens. These vaccines stimulate the immune system to recognize and combat infectious agents, helping reduce the incidence and severity of diseases. The large market share of this segment is driven by factors such as the increasing prevalence of chronic and infectious diseases, rising public awareness about immunization, growing immunization programs, the induction of herd immunity, and the prevention of disease outbreaks. For instance, in April 2024, the Pan American Health Organization (PAHO) launched the 22nd edition of Vaccination Week in the Americas (VWA) 2024, which included updates on vaccination coverage and efforts to return to pre-pandemic vaccination levels.
However, the therapeutic vaccines segment is expected to grow at the fastest CAGR during the forecast period. Therapeutic vaccines are administered to individuals already suffering from infections or diseases to help reduce symptoms and modify the course of the disease. These vaccines are primarily used to treat certain types of cancer. The growth of this segment is driven by factors such as the introduction of antiviral immunity to alter disease progression, high specificity and safety, low susceptibility to side effects, and cost-effectiveness.
By Indication: In 2024, the Influenza Segment to Dominate the Viral Vaccines Market
Based on indications, the market is segmented into influenza, human papilloma virus (HPV), rotavirus, poliomyelitis (polio), hepatitis, cancer, and other indications. In 2024, the influenza segment is expected to account for the largest share of 40% of the market. The large market share of this segment is attributed to factors such as increased awareness about the importance of influenza vaccination, growing government initiatives for influenza vaccination, and the rising number of clinical trials focused on influenza vaccines.
By Route of Administration: In 2024, the Intramuscular (IM) Segment to Dominate the Viral Vaccines Market
Based on routes of administration, the market is segmented into intramuscular (IM), subcutaneous (SC), oral, and other routes of administration. In 2024, the intramuscular (IM) segment is expected to account for the largest share of 89.5% of the viral vaccines market. Intramuscular injections are administered into muscle tissue below the dermis and subcutaneous tissue. Intramuscular injections are administered into muscle tissue beneath the dermis and subcutaneous layers and are typically given at two routinely recommended sites. The large market share of this segment is attributed to factors such as its ability to produce the desired immune response, its safety and tolerability, and its use for most inactivated vaccines. In May 2023, Merck & Co., Inc. (U.S.) received approval from the U.S. Food and Drug Administration (FDA) for the intramuscular administration of its MMRV vaccine family, including M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella, and Varicella Virus Vaccine Live).
By Packaging: In 2024, the Vials Segment to Dominate the Viral Vaccines Market
Based on packaging, the market is segmented into vials and prefilled syringes. In 2024, the vials segment is expected to account for a larger share of 93.2% of the viral vaccines market. Vials are small containers, typically made of plastic or glass, used to store liquid medications or powders. The large market share of this segment is driven by factors such as the protective environment vials provide, which helps maintain the stability and efficacy of vaccines by shielding them from moisture, light, and contamination. Vials also allow for visual inspection of contents before administration and feature tamper-proof packaging to prevent unauthorized access or tampering.
Geographical Analysis
By Geography: In 2024, North America to Dominate the Viral Vaccines Market
In 2024, North America is expected to account for the largest share of 45.6% of the viral vaccines market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America’s large market share is attributed to several factors, including the presence of leading manufacturers, significant investments in R&D, strong government and regulatory support, a rising number of infections, the availability of healthcare professionals to administer vaccines, and expanding immunization programs. For instance, in March 2021, Sanofi S.A. (Italy) announced a USD 925 million investment to expand its vaccine manufacturing operations in Toronto, Canada. This investment aims to boost the supply of Sanofi’s FLUZONE High-Dose Quadrivalent influenza vaccine, enhancing its antigen and filling capacity. The new facility will also serve as an international production and distribution hub for Sanofi's high-dose seasonal influenza vaccine.
However, Asia-Pacific is slated to register the highest CAGR of 10. 2% during the forecast period. This growth is driven by factors such as the rising emergence of infectious diseases, a large patient population, increasing public awareness of vaccination, and strong governmental support for immunization. For example, in October 2023, Singapore’s Health Sciences Authority (HSA) approved the updated Spikevax vaccine from Moderna, Inc. (U.S.) for COVID-19 prevention in individuals aged 6 months and older. Additionally, in March 2022, the Government of Thailand, in collaboration with the Pediatric Infectious Disease Society of Thailand (PIDST), launched an expanded immunization program (EPI) that now includes vaccines for BCG, HB, DTwP, Hib, OPV, Rota, MMR, Live JE, Influenza, and HPV for children.
Viral Vaccines Market: Key Companies
The report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios and geographic presence and the key growth strategies adopted by them over the past 3–4 years. Some of the key players operating in the viral vaccines market are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).
Viral Vaccines Industry Overview: Latest Developments from Key Industry Players
- In March 2024, Cadila Pharmaceuticals (India) launched the Cadiflu Tetra vaccine that was approved by the Drugs Controller General of India (DCGI) to be used in adults and children for protection against the Influenza virus.
- In November 2023, Valneva SE (France) received approval for its single-dose live attenuated IXCHIQ vaccine to prevent the disease caused by the chikungunya virus (CHIKV) in individuals aged 18 years and older.
- In May 2023, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline plc’s (U.K.) Arexvy, which is a respiratory syncytial virus (RSV) vaccine for use in the U.S. This is a preventive vaccine used for the prevention of lower respiratory tract diseases caused by RSV in individuals aged 60 years and above.
- In May 2023, the U.S FDA approved ABRYSVO, Pfizer, Inc.’s (U.S.) vaccine for the prevention of RSV in older adults.
Viral Vaccines Market Research Summary
|
Particulars |
Details |
|
Number of Pages |
239 |
|
Format |
|
|
Forecast Period |
2024–2031 |
|
Base Year |
2023 |
|
CAGR (Value) |
9.3% |
|
Market Size (Value) |
USD 64.18 Billion by 2031 |
|
Segments Covered |
By Form
By Vaccine Type
By Route of Administration
By Approach
By Indication
By Packaging
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Ireland, Denmark, Belgium, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
|
Key Companies |
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India) |
Key Questions Answered in the Viral Vaccines Market Report:
This market study covers the market sizes & forecasts of the viral vaccines market based on form, vaccine type, route of administration, indication, application, packaging, and geography. This market study also provides the value analysis of various segments and subsegments of the global viral vaccines market at the regional & country levels.
The viral vaccines market is projected to reach $64.18 billion by 2031, at a CAGR of 9.3% during the forecast period.
The liquid vaccines segment is expected to account for the largest share of the market in 2024. The large market share of this segment is attributed to factors such as reduced risk of errors, reduced wastage, improved patient experience, low production costs, and better stability.
Based on approach, the therapeutic vaccines segment is slated to register the highest CAGR in the market. The growth of the segment is attributed to factors such as the introduction of antiviral immunity to alter the course of the disease, high specificity and safety, and low costs of vaccines.
The growth of the viral vaccines market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments.
Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders.
The key players profiled in the viral vaccines market report are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), AstraZeneca plc (U.K.), CSL Limited (Australia), Merck & Co., Inc. (U.S.), Sanofi (France), Sinovac Biotech Ltd. (China), Moderna, Inc. (U.S.), Valneva SE (France), Dynavax Technologies Corporation (U.S.), EMERGENT BIOSOLUTIONS INC. (U.S.), Johnson & Johnson (U.S.), Bharat Biotech Ltd. (India), and Serum Institute of India Pvt. Ltd. (India).
Countries like China, Brazil, and India are expected to offer significant growth opportunities for the vendors in this market during the analysis period. This is due to factors such as the rising number of pharmaceutical and biopharmaceutical companies, growing patient population, increasing disposable income, rising awareness of vaccinations, growing immunization programs, and the increasing incidence of infectious diseases.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders From The Industry
2.3. Market Sizing & Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Drivers
4.2.1.1. Increasing Government Focus on Immunization Programs
4.2.1.2. Technological Advancements in Vaccine Administration
4.2.2. Restraints
4.2.2.1. High Costs of Vaccine Development
4.2.2.2. Long Timelines of Vaccine Manufacturing
4.2.3. Opportunities
4.2.3.1. Growing Focus on Therapeutic Vaccines
4.2.3.2. Increasing Use of Adjuvants in Vaccines
4.2.3.3. Growth Prospects in Emerging Markets
4.2.4. Challenges
4.2.4.1. Product Recalls
4.2.4.2. Inadequate Access to Vaccines
4.2.5. Key Trends
4.2.5.1. Personalized Vaccines and Vaccinomics
4.2.5.2. Media and Public Awareness Regarding Immunization
4.3. Regulatory Analysis
4.4. Pricing Analysis
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Buyers
4.5.2. Bargaining Power of Suppliers
4.5.3. Threat of Substitutes
4.5.4. Threat of New Entrants
4.5.5. Degree of Competition
4.6. Pipeline Analysis
5. Viral Vaccines Market Assessment—by Form
5.1. Overview
5.2. Liquid Viral Vaccines
5.3. Lyophilized Viral Vaccines
6. Viral Vaccines Market—by Vaccine Type
6.1. Overview
6.2. mRNA Vaccines
6.3. Subunit & Conjugate Vaccines
6.4. Live-attenuated Vaccines
6.5. Inactivated Vaccines
6.6. Viral Vector Vaccines
6.7. Combination Vaccines
7. Viral Vaccines Market Assessment—by Route of Administration
7.1. Overview
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other Routes of Administration
8. Viral Vaccines Market Assessment—by Approach
8.1. Overview
8.2. Preventive Vaccines
8.3. Therapeutic Vaccines
9. Viral Vaccines Market Assessment—by Indication
9.1. Overview
9.2. Influenza
9.3. Human Papillomavirus (HPV)
9.4. Rotavirus
9.5. Poliomyelitis (Polio)
9.6. Hepatitis
9.7. Cancer
9.8. Other Indications
10. Viral Vaccines Market Assessment—by Packaging
10.1. Overview
10.2. Vials
10.3. Prefilled Syringes
11. Coronavirus Disease
11.1. COVID-19: Overview
11.2. Coronavirus Prevalence
11.3. COVID-19 Market Assessment
12. Viral Vaccines Market Assessment—by Geography
12.1. Overview
12.2. North America
12.2.1. U.S.
12.2.2. Canada
12.3. Europe
12.3.1. Germany
12.3.2. U.K.
12.3.3. France
12.3.4. Italy
12.3.5. Spain
12.3.6. Switzerland
12.3.7. Ireland
12.3.8. Denmark
12.3.9. Belgium
12.3.10. Rest of Europe
12.4. Asia-Pacific
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. South Korea
12.4.5. Rest of Asia-Pacific
12.5. Latin America
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Middle East & Africa
13. Competitive Landscape
13.1. Introduction
13.2. Key Growth Strategies
13.3. Competitive Benchmarking
13.4. Competitive Dashboard
13.4.1. Industry Leaders
13.4.2. Market Differentiators
13.4.3. Vanguards
13.4.4. Emerging Companies
13.5. Market Share Analysis
14. Company Profiles
14.1. Pfizer Inc.
14.2. Glaxo Smith Kline plc
14.3. AstraZeneca plc
14.4. CSL Limited
14.5. Merck & Co., Inc.
14.6. Moderna, Inc.
14.7. Johnson & Johnson
14.8. Emergent Biosolutions Inc.
14.9. Bharat Biotech Ltd.
14.10. Sinovac Biotech Ltd.
14.11. Sanofi
14.12. Serum Institute of India Pvt. Ltd.
14.13. Dynavax Technologies Corporation
14.14. Valneva SE
15. Appendix
15.1. Available Customization
15.2. Related Reports
List Of Figures
Table 1 Estimated Number of Malaria Cases in Regions with Emerging Countries, 2022 (in Thousands)
Table 2 Number of People Living with HIV, by Region, 2022 (in Million)
Table 3 Key Government Agencies Regulating Vaccines
Table 4 Average Selling Prices of Key Vaccines, by Region (USD/UNIT)
Table 5 Viral Vaccines: Pipeline Analysis
Table 6 Global Viral Vaccines Market, by Form, 2022-2031 (USD Million)
Table 7 Global Liquid Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Companies Offering Lyophilized Viral Vaccines
Table 9 Global Lyophilized Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Viral Vaccines Market, by Vaccine Type, 2022-2031 (USD Million)
Table 11 Companies Offering mRNA Vaccines
Table 12 Global mRNA Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Companies Offering Subunit and Conjugate Vaccines
Table 14 Global Subunit & Conjugate Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Companies Offering Live-Attenuated Vaccines
Table 16 Global Live-Attenuated Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Key Companies Offering Inactivated Vaccines
Table 18 Global Inactivated Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Global Viral Vector Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Key Companies Offering Combination Vaccines
Table 21 Global Combination Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Global Viral Vaccines Market, by Route of Administration, 2022-2031 (USD Million)
Table 23 Intramuscular Sites For Vaccine Administration, by Age Group
Table 24 Global Intramuscular Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 25 Subcutaneous Sites For Vaccine Administration, by Age Group
Table 26 Global Subcutaneous Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 27 Key Companies Offering Oral Viral Vaccines
Table 28 Global Oral Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Viral Vaccines Market for Other Routes of Administration, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Viral Vaccines Market, by Approach, 2022-2031 (USD Million)
Table 31 Global Preventive Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
Table 32 Global Therapeutic Viral Vaccines Market, by Country/Region, 2022-2031 (USD Million)
Table 33 Global Viral Vaccines Market, by Indication, 2022-2031 (USD Million)
Table 34 Global Viral Vaccines Market For Influenza, by Country/Region, 2022-2031 (USD Million)
Table 35 Global Viral Vaccines Market For Human Papillomavirus (HPV), by Country/Region, 2022-2031 (USD Million)
Table 36 Global Viral Vaccines Market For Rotavirus, by Country/Region, 2022-2031 (USD Million)
Table 37 Global Viral Vaccines Market For Poliomyelitis, by Country/Region, 2022-2031 (USD Million)
Table 38 Global Viral Vaccines Market For Hepatitis, by Country/Region, 2022-2031 (USD Million)
Table 39 Global NUMBER of New Cancer Cases, 2022–2030
Table 40 Global Viral Vaccines Market For Cancer, by Country/Region, 2022-2031 (USD Million)
Table 41 Global Viral Vaccines Market For Other Indications, by Country/Region, 2022-2031 (USD Million)
Table 42 Global Viral Vaccines Market, by Packaging, 2022-2031 (USD Million)
Table 43 Global Viral Vaccine Vials Market, by Country/Region, 2022-2031 (USD Million)
Table 44 Global Prefilled Viral Vaccine Syringes Market, by Country/Region, 2022-2031 (USD Million)
Table 45 COVID-19: Overview
Table 46 Coronavirus Confirmed Cases, by Region (As of April 2024)
Table 47 Global Viral Vaccines Market FOR COVID-19, by Country/Region, 2022–2031 (USD Million)
Table 48 Global Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 49 North America: Viral Vaccines Market, by Country, 2022–2031 (USD Million)
Table 50 North America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 51 North America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 52 North America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 53 North America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 54 North America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 55 North America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 56 U.S.: Accelerated Approval Dates of Vaccines By The U.S. FDA
Table 57 U.S.: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 58 U.S.: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 59 U.S.: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 60 U.S.: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 61 U.S.: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 62 U.S.: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 63 Canada: Influenza Cases, 2023-2024, Week 1-34
Table 64 Canada: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 65 Canada: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 66 Canada: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 67 Canada: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 68 Canada: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 69 Canada: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 70 Europe: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 71 Europe: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 72 Europe: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 73 Europe: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 74 Europe: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 75 Europe: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 76 Europe: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 77 Germany: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 78 Germany: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 79 Germany: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 80 Germany: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 81 Germany: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 82 Germany: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 83 U.K.: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 84 U.K.: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 85 U.K.: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 86 U.K.: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 87 U.K.: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 88 U.K.: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 89 France: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 90 France: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 91 France: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 92 France: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 93 France: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 94 France: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 95 Italy: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 96 Italy: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 97 Italy: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 98 Italy: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 99 Italy: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 100 Italy: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 101 Spain: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 102 Spain: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 103 Spain: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 104 Spain: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 105 Spain: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 106 Spain: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 107 Switzerland: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 108 Switzerland: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 109 Switzerland: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 110 Switzerland: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 111 Switzerland: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 112 Switzerland: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 113 Ireland: Number of Infectious Diseases Notifications (2019-2023)
Table 114 Ireland: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 115 Ireland: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 116 Ireland: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 117 Ireland: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 118 Ireland: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 119 Ireland: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 120 Denmark: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 121 Denmark: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 122 Denmark: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 123 Denmark: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 124 Denmark: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 125 Denmark: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 126 Belgium: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 127 Belgium: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 128 Belgium: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 129 Belgium: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 130 Belgium: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 131 Belgium: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 132 Rest of Europe: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 133 Rest of Europe: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 134 Rest of Europe: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 135 Rest of Europe: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 136 Rest of Europe: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 137 Rest of Europe: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 138 Asia-Pacific: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 139 Asia-Pacific: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 140 Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 141 Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 142 Asia-Pacific: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 143 Asia-Pacific: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 144 Asia-Pacific: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 145 Japan: Key Macroindicators & Microindicators
Table 146 Japan: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 147 Japan: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 148 Japan: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 149 Japan: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 150 Japan: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 151 Japan: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 152 China: Key Macroindicators & Microindicators
Table 153 China: Key Immunization Indicators
Table 154 China: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 155 China: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 156 China: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 157 China: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 158 China: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 159 China: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 160 India: Key Macroindicators & Microindicators
Table 161 India: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 162 India: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 163 India: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 164 India: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 165 India: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 166 India: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 167 South Korea: Key Macroindicators & Microindicators
Table 168 South Korea: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 169 South Korea: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 170 South Korea: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 171 South Korea: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 172 South Korea: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 173 South Korea: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 174 Bangladesh: Key Immunization Indicators
Table 175 Nepal: Key Immunization Indicators
Table 176 Rest of Asia-Pacific: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 177 Rest of Asia-Pacific: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 178 Rest of Asia-Pacific: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 179 Rest of Asia-Pacific: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 180 Rest of Asia-Pacific: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 181 Latin America: Viral Vaccines Market, by Country/Region, 2022–2031 (USD Million)
Table 182 Latin America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 183 Latin America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 184 Latin America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 185 Latin America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 186 Latin America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 187 Latin America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 188 Brazil: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 189 Brazil: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 190 Brazil: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 191 Brazil: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 192 Brazil: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 193 Brazil: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 194 Mexico: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 195 Mexico: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 196 Mexico: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 197 Mexico: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 198 Mexico: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 199 Mexico: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 200 Rest of Latin America: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 201 Rest of Latin America: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 202 Rest of Latin America: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 203 Rest of Latin America: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 204 Rest of Latin America: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 205 Rest of Latin America: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 206 Middle East & Africa: Viral Vaccines Market, by Form, 2022–2031 (USD Million)
Table 207 Middle East & Africa: Viral Vaccines Market, by Vaccine Type, 2022–2031 (USD Million)
Table 208 Middle East & Africa: Viral Vaccines Market, by Route of Administration, 2022–2031 (USD Million)
Table 209 Middle East & Africa: Viral Vaccines Market, by Approach, 2022–2031 (USD Million)
Table 210 Middle East & Africa: Viral Vaccines Market, by Indication, 2022–2031 (USD Million)
Table 211 Middle East & Africa: Viral Vaccines Market, by Packaging, 2022–2031 (USD Million)
Table 212 Recent Developments, by Company (2021-2024)
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for this Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approaches
Figure 7 Global Viral Vaccines Market, by Indication, 2024 Vs.2031 (USD Million)
Figure 8 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
Figure 9 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
Figure 10 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 11 Global Viral Vaccines Market, by Approach, 2024 Vs. 2031 (USD Million)
Figure 12 Global Viral Vaccines Market, by Packaging, 2024 Vs. 2031 (USD Million)
Figure 13 Global Viral Vaccines Market, by Geography
Figure 14 Impact Analysis of Market Dynamics
Figure 15 Porter’s Five Forces Analysis
Figure 16 Global Viral Vaccines Market, by Form, 2024 Vs. 2031 (USD Million)
Figure 17 Global Viral Vaccines Market, by Vaccine Type, 2024 Vs. 2031 (USD Million)
Figure 18 Global Viral Vaccines Market, by Route of Administration, 2024 Vs. 2031 (USD Million)
Figure 19 Global Viral Vaccines Market, by Approach, 2024 VS. 2031 (USD Million)
Figure 20 Global Viral Vaccines Market, by Indication, 2024 VS. 2031 (USD Million)
Figure 21 Global Viral Vaccines Market, by Packaging, 2024 VS. 2031 (USD Million)
Figure 22 Global Viral Vaccines Market, by GEOGRAPHY, 2024 VS. 2031 (USD Million)
Figure 23 North America: Viral Vaccines Market Snapshot
Figure 24 Europe: Viral Vaccines Market Snapshot
Figure 25 Asia-Pacific: Viral Vaccines Market Snapshot
Figure 26 Number of Cases Reported for Dengue, 2019-2023
Figure 27 Latin America: Viral Vaccines Market Snapshot
Figure 28 Saudi Arabia Viral Vaccination Coverage (2023)
Figure 29 Key Growth Strategies Adopted By Leading Players, 2021-2024
Figure 30 Viral Vaccines Market: Competitive Benchmarking (Based On Indications)
Figure 31 Viral Vaccines Market: Competitive Benchmarking (BASED ON Region)
Figure 32 Competitive Dashboard: Viral Vaccines Market
Figure 33 Market Share Analysis: Viral Vaccines Market (with Covid-19 Vaccines), 2023
Figure 34 Market Share Analysis: Viral Vaccines Market (Without Covid-19 Vaccines), 2023
Figure 35 Pfizer Inc.: Financial Snapshot (2023)
Figure 36 Glaxo Smith Kline Plc: Financial Overview (2023)
Figure 37 AstraZeneca Plc: Financial Overview (2023)
Figure 38 CSL LIMITED: Financial Overview (2024)
Figure 39 Merck & Co., Inc.: Financial Overview (2023)
Figure 40 Moderna, Inc.: Financial Snapshot (2023)
Figure 41 Johnson & Johnson: Financial Snapshot (2023)
Figure 42 Emergent Biosolutions Inc.: Financial Snapshot (2023)
Figure 43 Sinovac Biotech Ltd.: Financial Overview (2023)
Figure 44 Sanofi: Financial Overview (2023)
Figure 45 Dynavax Technologies Corporation: Financial Snapshot (2023)
Figure 46 Valneva SE: Financial Snapshot (2023)
Author Name:
Viral Vaccines Market is Expected to Grow at a CAGR of 9.3% from 2024 to 2031 to Reach $64.18 Billion by 2031, according to Meticulous Research®.
According to this latest publication from Meticulous Research®, the global viral vaccines market is expected to grow at a CAGR of 9.3% from 2024 to 2031 to reach $64.18 billion by 2031. The growth of this market is driven by the increasing government focus on immunization programs, technological advances in vaccine administration, and the use of inactivated vaccines in surgeries and treatments. However, the high costs of vaccine development and the long timelines of vaccine manufacturing restrain the growth of this market.
Furthermore, the growing focus on therapeutic vaccines, this increasing use of adjuvants in vaccines, growth prospects in emerging markets, and the development of highly stable and energy-efficient ultra-low-temperature freezers are expected to generate growth opportunities for market stakeholders. However, product recalls and inadequate access to vaccines are major challenges impacting the market’s growth.
Pfizer, Inc. (U.S.)
Founded in 1942 and headquartered in New York, U.S., Pfizer Inc. is a leading biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sale, and distribution of biopharmaceutical products. The company operates primarily in two segments: Biopharma and Business Innovation. Within the Biopharma segment, Pfizer has structured its operations into three key divisions: the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. The company offerings are categorized into Primary Care, Specialty Care, and Oncology. Notably, Pfizer's Primary Care division plays an active role in the viral vaccines market.
Pfizer has a strong geographic presence, with operations in China, Japan, Ireland, Belgium, Germany, Singapore, India, and other countries. The company operates 37 manufacturing plants across the globe, with production facilities in countries such as Belgium, Germany, India, Ireland, Italy, Japan, Singapore, and the U.S., along with multiple distribution centers worldwide. Key subsidiaries include Agouron Pharmaceuticals, LLC (U.S.), Pfizer Pharmaceuticals Israel Ltd. (Israel), Pfizer S.r.l. (Italy), Pfizer PFE Australia Pty Ltd (Australia), Arena Pharmaceuticals Development GmbH (Switzerland), Pfizer Japan Inc. (Japan), Pfizer Limited (U.K.), Pfizer Laboratories Limited (Kenya), and Pfizer (China) Research and Development Co. Ltd. (China).
GlaxoSmithKline plc (U.K.)
Founded in 2000 and headquartered in Brentford, U.K., GlaxoSmithKline (GSK) plc is a biopharmaceutical company engaged in the research, development, identification, and testing of discoveries, as well as the manufacturing and commercialization of medicines. The company operates across three main business segments: Vaccines, Specialty Medicines, and General Medicines. Through its Vaccines segment, GSK offers a variety of viral vaccines. The company employs a broad range of vaccine technologies, including MAPS, mRNA, and adjuvants, to develop tailored vaccines for various diseases.
GSK plc has a geographic presence across 75 countries worldwide, such as the U.A.E, Kenya, Argentina, Brazil, Canada, Mexico, Israel, Bangladesh, India, China, New Zealand, Singapore, Japan, and Malaysia, among others. The company has 33 manufacturing sites and four global R&D centers. As of December 2023, 22,000 worldwide suppliers are associated with the company for the distribution cycle. Some of the company’s major subsidiaries are Affinivax, Inc. (U.S.), GlaxoSmithKline Pharmaceuticals Ltd (India), GSK Vaccines GmbH (Germany), GSK Vaccines S.r.l. (Italy), GSK Pharma India Private Limited (India), GSK Life Sciences FZE (UAE), and SmithKline Beecham Pharmaceuticals Co. (U.S.).
AstraZeneca plc (U.K.)
Formed in 1999 after the merger of Astra AB and Zeneca PLC and headquartered in Cambridge, U.K., AstraZeneca plc is a pharmaceutical business company involved in the research, development, manufacturing, and commercialization of medicines. The company operates its pharmaceuticals business through a single segment. It focuses on therapy areas like Oncology, Biopharmaceuticals, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, and Vaccines & Immune Therapies and Rare Diseases. The company offers viral vaccines through its Vaccines & Immune Therapies segment.
AstraZeneca plc has a geographic presence across 125 countries worldwide. The company has a commercial operational presence in over 85 countries, including U.S., Belgium, Bulgaria, France, Italy, Poland, Sweden, Croatia, Germany, Latvia, Portugal, Switzerland, Australia, Canada, Japan, New Zealand, Brazil, Hong Kong, Mongolia, South Africa, Vietnam, and many others. Major subsidiaries of the company include AstraZeneca Ireland Limited (Ireland), Simesa SpA (Italy), AstraZeneca Pharmaceuticals Limited (Kenya), Alexion Europe SAS (France), Portola Netherlands B.V. (Netherlands), AstraZeneca Korea Co. Ltd (South Korea), AstraZeneca AB (Sweden), Ardea Biosciences, Inc. (U.S.), and AstraZeneca Pharma India Limited (India).
CSL Limited (Australia)
Founded in 1916 and headquartered in Melbourne, Australia, CSL Limited is a biotechnology company with a dynamic portfolio of life-saving medicine to treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. The company focuses on three major areas of health: rare and serious diseases, influenza vaccines, and iron deficiency and nephrology.
The company operates in three businesses: CSL Behring, CSL Seqirus, and CSL Vifor. Through the vaccines of the CSL Seqirus business, the company provides viral vaccines. This business is majorly involved in preventing influenza globally and is a transcontinental partner in pandemic preparedness. The company provides medicines and products to patients in 100 countries and employs more than 32,000 people.
The company has a robust geographical presence worldwide. Some of the subsidiaries of the company are Seqirus (Australia) Pty Ltd (Australia), Seqirus Pty Ltd (Australia), Laboratorios Seqirus S.A. (Argentina), Seqirus Canada Inc (Canada), Seqirus Korea Limited (South Korea), Seqirus Netherlands B.V. (Netherlands), Seqirus GmbH (Germany), Seqirus S.r.l (Italy), Seqirus Spain, S.L. (Spain), Seqirus AG (Switzerland), Seqirus Limited (U.K.), Seqirus Inc. (U.S.), among others.
Merck & Co., Inc. (U.S.)
Founded in 1891 and headquartered in New York, U.S., Merck & Co., Inc. is a global healthcare company focused on delivering innovative health solutions through its prescription medicines, including biologic therapies, vaccines, and animal health products. The company operates globally through two major segments: Pharmaceutical and Animal Health. The Pharmaceutical segment encompasses human health pharmaceuticals and vaccine products, with viral vaccines offered through this division. Merck sells its human health vaccines to physicians, wholesalers, distributors, and government entities.
The company has a geographic presence across 141 countries. The Healthcare business segment has 52 manufacturing sites and over 100 distribution centers. Some of its subsidiaries are Merck Healthcare Germany GmbH (Germany), Chord Therapeutics SA (Switzerland), Merck Healthcare Pty. Ltd. (Australia), Merck Biopharma Co., Ltd. (Japan), Merck Healthcare Vietnam Limited (Vietnam), and Merck Healthcare and Life Science Limited (Kenya).
Moderna, Inc. (U.S.)
Founded in 2010 and headquartered in Massachusetts, U.S., Moderna is a provider of messenger RNA (mRNA) vaccines. The company’s mRNA platform enables the development of therapeutics and vaccines for autoimmune diseases, infectious diseases, immuno-oncology, and rare diseases. The company is focused on multiple disease areas and advancing a broad and diverse product portfolio and therapeutics pipeline. The company’s current pipeline includes 45 therapeutics and vaccines, out of which nine are in late-stage development. The company was the earliest to develop COVID-19 vaccines. The company has 230 solely owned patents in the U.S. and more than 170 granted patents outside the U.S.
The company’s major subsidiaries include Moderna Australia Pty Ltd (Australia), Moderna Biopharma Canada Corporation (Canada), Moderna Biotech Kenya Manufacturing Ltd. (Kenya), Moderna Biotech Manufacturing UK Ltd (U.K.), Moderna Biotech Singapore Pte. Ltd. (Singapore), Moderna Biotech Spain, S.L.U. (Spain), Moderna Denmark ApS (Denmark), Moderna Germany GmbH (Germany), Moderna Italy S.r.l. (Italy), Moderna Japan Co., Ltd. (Japan), Moderna US, Inc. (Delaware), and Moderna Taiwan Co., Ltd (Taiwan).
Johnson & Johnson (U.S.) :
Founded in 1886 and headquartered in New Jersey, U.S., Johnson & Johnson is a healthcare company engaged in the research & development, manufacturing, and sale of healthcare products. The company operates through two business segments, namely Innovative Medicine and MedTech. The Innovative Medicine segment is focused on therapeutic areas such as immunology, infectious diseases, neuroscience, oncology, cardiovascular health, metabolism, and pulmonary hypertension. Johnson & Johnson provides viral vaccines through the Innovative Medicine segment.
Johnson & Johnson has a geographic presence across the U.S., Europe, the Western Hemisphere, Africa, Asia, and the Pacific region. Furthermore, the company has 61 facilities globally, of which 18 facilities are used by the Innovative Medicine segment, and the other 43 facilities are used by the MedTech segment. The company’s major subsidiaries include Actelion Pharmaceuticals US, Inc. (U.S.), Anakuria Therapeutics, Inc. (U.S.), Biosense Webster, Inc. California (U.S.), Janssen Biotech, Inc. (U.S.), Actelion Pharmaceuticals Ltd (Switzerland), Ethicon Women's Health & Urology Sarl (Switzerland), GBSC Division of Janssen Biologics B.V. (Netherlands), and Guangzhou Bioseal Biotech Co., Ltd. (China).
EMERGENT BIOSOLUTIONS INC. (U.S.)
Founded in 1998 and headquartered in Maryland, U.S., EMERGENT BIOSOLUTIONS INC. is a specialty biopharmaceutical & life sciences company focused on protecting and enhancing life by providing products and solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The company operates through 3 reportable business segments, namely Commercial Products, MCM Products, and Services. The company provides viral vaccine products through the MCM Products segments.
The company has a geographical presence across North America in Lansing, Michigan, Maryland, Massachusetts, Winnipeg, and Manitoba through its 17 manufacturing facilities and across Europe, the Middle East, Asia, and the Pacific Rim through its distributors. The company’s major domestic subsidiaries include Emergent Commercial Operations Frederick Inc. (Maryland), Emergent Biodefense Operations Lansing LLC (Delaware), Emergent Europe Inc. (Delaware), Emergent International Inc. (Delaware), Emergent Product Development Gaithersburg Inc. (Delaware), Emergent Protective Products USA Inc. (Delaware), and Emergent Travel Health Inc. (Delaware).
Bharat Biotech Ltd. (India)
Formed in 1996 and headquartered in Hyderabad, India, Bharat Biotech Ltd. is a developer of innovative vaccines and bio-therapeutics. The company owns 220 Patents and has a geographic presence in over 125 countries. The company’s manufacturing facilities have been approved by the U.S. FDA, KFDA, and WHO.
The company’s manufacturing facilities are located in Telangana, Gujarat, Karnataka, and Maharashtra in India. The company’s manufacturing facilities use microbial cultures such as E.coli and recombinant yeast. Apart from microbes, the company also uses raw materials such as peptone, sucrose, EDTA, Tris Buffer, and sodium chloride.
Sinovac Biotech Ltd. (China)
Incorporated in 2001 and headquartered in Beijing, China, Sinovac Biotech Ltd. is a biopharmaceutical company engaged in the research, development, production, and marketing of vaccines that protect against infectious diseases. The company operates through one reportable business segment and serves three business markets, namely, Expanded Program of Immunization (EPI), Private Pay, and Export. The EPI includes vaccines that are inoculated to residents with government provisions. The Private Pay market includes other vaccines that are voluntarily inoculated by individuals.
The company has a strong geographic presence in China and internationally in Singapore, Hong Kong, Thailand, the Philippines, Bangladesh, Indonesia, and Chile. The company has manufacturing sites, R&D centers, and production sites primarily in China. Some of the company’s subsidiaries are Sinovac Beijing Co., Ltd. (China), Sinovac (Dalian) Vaccine Technology Co., Ltd. (China), Sinovac Life Sciences Co., Ltd. (China), and Sinovac Biomed Co., Lt
Acess Full Report @ https://www.meticulousresearch.com/product/viral-vaccines-market-5920
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Anesthesia Machines Market - Global Opportunity Analysis and Industry Forecast (2025-2032)
Published Date: Jan-2025
Veterinary Vaccines Market - Global Opportunity Analysis and Industry Forecast (2025-2032)
Published Date: Jan-2025
Vaccines Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Vaccine Storage Equipment Market - Global Opportunity Analysis and Industry Forecast (2020-2027)
Published Date: Jan-2021
Continuous Bioprocessing Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: Mar-2024
